Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

4.360 -0.350 (-7.43%)
Streaming Delayed Price Updated: 2:51 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Earnings Scheduled For November 26, 2021 ↗
Companies Reporting Before The Bell Pinduoduo Inc. (NASDAQ:PDD) is expected to report quarterly earnings at $0.02 per share on revenue of $4.16 billion. BlueCity Holdings Limited... 
Via Benzinga
News headline image
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite's Kickstarts Piclidenoson Study For Canine Osteoarthritis ↗
Can-Fite BioPharma Ltd (NYSE: CANF) has commenced a safety and efficacy study of Piclidenoson to treat osteoarthritis in dogs. Safety results are expected in... 
Via Benzinga
News headline image
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal ↗
PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule... 
Via Benzinga
News headline image
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Hope on the Horizon for Liver Cancer Patients as This Company's Namodenoson Drug Starts Pivotal Phase III Global Trial ↗
Photo by National Cancer Institute on Unsplash Liver cancer is a growing global health concern. Apart from the financial burden it places on patients and economies, the American... 
Via Benzinga
News headline image
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
The Week In Cannabis: $1.25B+ In Financings And M&A, Tilray, KushCo, New York And More ↗
Below is a recap of the main news related to the cannabis industry and markets for the week of August 27, 2021. 
Via Benzinga
Topics Cannabis
News headline image
Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY ↗
Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021. The Israel-based company... 
Via Benzinga
News headline image
Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Announces $10.0 Million Registered Direct Offering
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
News headline image
Can-Fite Stock Gains On Piclidenoson Development Pact For Pets ↗
Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to... 
Via Benzinga
News headline image
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS ↗
Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In... 
Via Benzinga
News headline image
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
CAN-FITE BIOPHARMA ANNOUNCES ADVANCEMENT OF CLINICAL STUDIES AND NEW EUROPEAN LICENSING AGREEMENTS ↗
by Mark Gilman Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), an Israeli-based biotechnology company advancing a pipeline of proprietary small-molecule drugs that address... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.